To investigate the possibility that proteins involved in the ubiquitylation machinery modulated the tumour cell response to a clinical PARP inhibitor, olaparib [3, 12], we first reanalyzed data from a previously published genome-wide olaparib sensitization genetic screen [8]. Here, PARP1 is linked to neoplasm.